Wally R. Smith, MD: Agios Pharamaceuticals: Consultant/Advisory Board (Ongoing), Research Grant (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (Ongoing); Pfizer: Consultant/Advisory Board (Ongoing), Research Grant (Ongoing)
Learning Objectives:
1. List the most common Mental health comorbidities in patients with sickle cell disease
2. Explain How Mental health becomes disordered in patients with sickle cell disease, especially from institutional racism and trauma
3. Learn to listen to the patient’s voice and beliefs in order to improve SCD mental health
4. Describe an approach to treatment of common mental health disorders and pain-complications in sickle cell disease
5. Explain how important mental health evaluations will be in selecting patient candidates and succeeding in Gene Rx